• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血浆生物标志物可识别无痴呆症的基于人群队列中的脑淀粉样蛋白、tau蛋白和神经退行性变异常。

Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort.

作者信息

Dresse Menayit Tamrat, Ferreira Pamela C L, Prasadan Akshay, Diaz Jihui L, Zeng Xuemei, Bellaver Bruna, Povala Guilherme, Villemagne Victor L, Kamboh M Ilyas, Cohen Ann D, Pascoal Tharick A, Ganguli Mary, Snitz Beth E, Shaaban C Elizabeth, Karikari Thomas K

机构信息

Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, 15213, USA.

Department of Psychiatry, School of Medicine, University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.

出版信息

Alzheimers Res Ther. 2025 Jul 25;17(1):173. doi: 10.1186/s13195-025-01803-w.

DOI:10.1186/s13195-025-01803-w
PMID:40713737
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12291478/
Abstract

INTRODUCTION

Using the ATN framework, we evaluated the potential of plasma biomarkers to identify abnormal brain amyloid-beta (Aβ) positron emission tomography (PET), tau-PET and neurodegeneration in a socioeconomically disadvantaged population-based cohort.

METHODS

Community-dwelling dementia-free (n = 113, including 102 (91%) cognitively normal) participants underwent ATN neuroimaging and plasma biomarker assessments.

RESULTS

Plasma Aβ42/Aβ40, p-tau181, and p-tau217 showed significant associations with Aβ-PET status, (adjusted odds ratio [AOR] of 1.7410, 1.47, and 3.4310, respectively (p-values < 0.05), with p-tau217 demonstrating the highest classification accuracy for Aβ-PET status (AUC = 0.94). Plasma p-tau181 and p-tau217 showed significant associations with tau-PET status (AOR: 1.50 and 22.24, respectively (p-values < 0.05), with comparable classification accuracies for tau-PET status (AUC = 0.74 and 0.70, respectively). Only plasma NfL showed significant association with neurodegeneration based on cortical thickness (AOR = 1.09, p-value < 0.05).

CONCLUSION

Our findings highlight the potential of plasma p-tau217 as a biomarker for brain Aβ and tau pathophysiology, p-tau181 for tau abnormalities, and NfL for neurodegeneration in the community.

摘要

引言

我们使用ATN框架,在一个社会经济地位不利的人群队列中,评估了血浆生物标志物识别异常脑淀粉样β蛋白(Aβ)正电子发射断层扫描(PET)、tau-PET和神经退行性变的潜力。

方法

居住在社区且无痴呆症的参与者(n = 113,包括102名(91%)认知正常者)接受了ATN神经影像学和血浆生物标志物评估。

结果

血浆Aβ42/Aβ40、p-tau181和p-tau217与Aβ-PET状态显示出显著相关性(调整后的优势比[AOR]分别为1.74×10、1.47和3.43×10(p值<0.05)),其中p-tau217对Aβ-PET状态的分类准确性最高(曲线下面积[AUC]=0.94)。血浆p-tau181和p-tau217与tau-PET状态显示出显著相关性(AOR分别为1.50和22.24(p值<0.05)),对tau-PET状态的分类准确性相当(AUC分别为0.74和0.70)。仅血浆神经丝轻链(NfL)与基于皮质厚度的神经退行性变显示出显著相关性(AOR = 1.09,p值<0.05)。

结论

我们的研究结果突出了血浆p-tau217作为脑Aβ和tau病理生理学生物标志物、p-tau181作为tau异常生物标志物以及NfL作为社区神经退行性变生物标志物的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d5a/12291478/9a0ca47d5f92/13195_2025_1803_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d5a/12291478/9de5610cad35/13195_2025_1803_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d5a/12291478/4d24a3c139bc/13195_2025_1803_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d5a/12291478/9a0ca47d5f92/13195_2025_1803_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d5a/12291478/9de5610cad35/13195_2025_1803_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d5a/12291478/4d24a3c139bc/13195_2025_1803_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d5a/12291478/9a0ca47d5f92/13195_2025_1803_Fig3_HTML.jpg

相似文献

1
Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort.血浆生物标志物可识别无痴呆症的基于人群队列中的脑淀粉样蛋白、tau蛋白和神经退行性变异常。
Alzheimers Res Ther. 2025 Jul 25;17(1):173. doi: 10.1186/s13195-025-01803-w.
2
Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort.血浆生物标志物可在无痴呆的基于人群的队列中识别脑淀粉样蛋白、tau蛋白和神经退行性变异常。
medRxiv. 2025 Apr 28:2025.04.27.25326360. doi: 10.1101/2025.04.27.25326360.
3
The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity.肾功能对阿尔茨海默病血液生物标志物的影响:对预测淀粉样蛋白-β阳性的意义。
Alzheimers Res Ther. 2025 Feb 19;17(1):48. doi: 10.1186/s13195-025-01692-z.
4
Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrum.血浆磷酸化tau217与阿尔茨海默病谱系中的记忆缺陷密切相关。
Brain. 2025 Jan 29. doi: 10.1093/brain/awaf033.
5
Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study.利用血浆生物标志物预测唐氏综合征患者的淀粉样蛋白和tau蛋白脑沉积及认知衰退:一项纵向队列研究。
Lancet Neurol. 2025 Jul;24(7):591-600. doi: 10.1016/S1474-4422(25)00158-9.
6
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment.血浆磷酸化 tau 217 和 Aβ42/40 预测认知正常人群的早期脑 Aβ 蓄积。
JAMA Neurol. 2024 Sep 1;81(9):947-957. doi: 10.1001/jamaneurol.2024.2619.
7
Diagnostic Performance of Eight Blood-based Biomarkers in a Well-characterized Korean Cohort of Preclinical Alzheimer's Disease.八项血液生物标志物在特征明确的韩国临床前阿尔茨海默病队列中的诊断性能
Ann Lab Med. 2025 May 12. doi: 10.3343/alm.2024.0498.
8
Clinical utility of plasma p-tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease.血浆p-tau217在伴有高发性脑血管疾病的亚洲队列中识别异常脑淀粉样蛋白负荷的临床效用
Alzheimers Dement. 2025 Feb;21(2):e14502. doi: 10.1002/alz.14502. Epub 2025 Jan 14.
9
Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer's disease.多分析物蛋白质组学分析鉴定出临床前阿尔茨海默病患者血液中的神经炎症、脑血管和突触生物标志物。
Mol Neurodegener. 2024 Oct 10;19(1):68. doi: 10.1186/s13024-024-00753-5.
10
Influence of medical conditions on the diagnostic accuracy of plasma p-tau217 and p-tau217/Aβ42.身体状况对血浆p-tau217和p-tau217/Aβ42诊断准确性的影响。
Alzheimers Dement. 2025 Feb;21(2):e14430. doi: 10.1002/alz.14430. Epub 2024 Dec 6.

引用本文的文献

1
Plasma biomarkers, brain amyloid pathology, and cortical thickness in a diverse middle-aged community cohort: the HCP-CoBRA study.一个多样化的中年社区队列中的血浆生物标志物、脑淀粉样蛋白病理学和皮质厚度:健康与退休研究社区脑淀粉样血管病变研究(HCP-CoBRA研究)
medRxiv. 2025 Jul 11:2025.07.10.25331312. doi: 10.1101/2025.07.10.25331312.

本文引用的文献

1
Treatment of Alzheimer Disease.阿尔茨海默病的治疗
Continuum (Minneap Minn). 2024 Dec 1;30(6):1823-1844. doi: 10.1212/CON.0000000000001503.
2
Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.用于阿尔茨海默病病理的主要血液检测的头对头比较。
Alzheimers Dement. 2024 Nov;20(11):8074-8096. doi: 10.1002/alz.14315. Epub 2024 Oct 12.
3
Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer's disease.多分析物蛋白质组学分析鉴定出临床前阿尔茨海默病患者血液中的神经炎症、脑血管和突触生物标志物。
Mol Neurodegener. 2024 Oct 10;19(1):68. doi: 10.1186/s13024-024-00753-5.
4
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission.《痴呆症的预防、干预与照护:柳叶刀常设委员会2024年报告》
Lancet. 2024 Aug 10;404(10452):572-628. doi: 10.1016/S0140-6736(24)01296-0. Epub 2024 Jul 31.
5
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment.血浆磷酸化 tau 217 和 Aβ42/40 预测认知正常人群的早期脑 Aβ 蓄积。
JAMA Neurol. 2024 Sep 1;81(9):947-957. doi: 10.1001/jamaneurol.2024.2619.
6
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准:阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
7
Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia.血浆中的胶质纤维酸性蛋白(GFAP)、神经丝轻链蛋白(NfL)和磷酸化tau蛋白181可检测痴呆的临床前期阶段。
Front Endocrinol (Lausanne). 2024 Apr 9;15:1375302. doi: 10.3389/fendo.2024.1375302. eCollection 2024.
8
Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease.血浆脑源性 tau 是阿尔茨海默病中与淀粉样蛋白相关的神经退行性变生物标志物。
Nat Commun. 2024 Apr 4;15(1):2908. doi: 10.1038/s41467-024-47286-5.
9
Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort.在一个记忆门诊队列中,对血浆和脑脊液 p-tau217 与 p-tau181 和 p-tau231 的诊断准确性进行头对头研究。
J Neurol. 2024 Apr;271(4):2053-2066. doi: 10.1007/s00415-023-12148-5. Epub 2024 Jan 9.
10
Plasma p-tau217, p-tau181, and NfL as early indicators of dementia risk in a community cohort: The Shanghai Aging Study.血浆p-tau217、p-tau181和神经丝轻链作为社区队列中痴呆风险的早期指标:上海老龄化研究
Alzheimers Dement (Amst). 2023 Dec 22;15(4):e12514. doi: 10.1002/dad2.12514. eCollection 2023 Oct-Dec.